<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066156</url>
  </required_header>
  <id_info>
    <org_study_id>2009-P-001664</org_study_id>
    <nct_id>NCT01066156</nct_id>
  </id_info>
  <brief_title>Post-Traumatic Stress Disorder (PTSD) and Seroquel</brief_title>
  <official_title>Functional Reciprocity Between Heightened Stress Reactivity and Emotional Numbing in PTSD: Novel Predictors of Pharmacotherapeutic Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge Health Alliance</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 8 weeks study will investigate therapeutic responses to Seroquel pharmacotherapy in
      PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An initial telephone interview will be conducted to determine if potential subjects meet the
      basic study requirements. If no obvious counterindications are present, subjects will be
      scheduled for a screening visit. After briefing the subjects on the reasons for the research,
      they will be given an opportunity to read the Informed Consent Form, approved by the
      Cambridge Health Alliance Institutional ReviewBoard, and to ask questions prior to signing
      it. Subjects will be given a copy of the signed Consent Form. Each subject will complete a
      standardized interview schedule designed to obtain personal and background data along with
      psychodiagnostic and psychometric evaluations. An open-label treatment will be utilized for
      all patients. Seroquel tablets will be flexibly dosed and begun at a target dose of 25 mg per
      day and taken over an 8 week period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint.</measure>
    <time_frame>8 weeks</time_frame>
    <description>We will compare patients' symptomatology at baseline vs. at 8 week timepoint
Specify Full Scale Name and Construct (i.e., indicate what the scale measures if not clear from name): Clinician-Administered PTSD Scale (CAPS)
Include all scale ranges (i.e., minimum and maximum scores) required to interpret any values in the data table: 0-136
For each scale range provided, specify which values are considered to be a better or worse outcome: 0-best, 136 worst
If subscales are combined to compute a total score, consider indicating how subscales are combined (summed, averaged, etc.): summed</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Seroquel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seroquel</intervention_name>
    <description>This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD</description>
    <arm_group_label>Seroquel</arm_group_label>
    <other_name>quetiapine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent

          -  Fluency in English

          -  A diagnosis of PTSD

          -  No pregnancy

          -  Right-handedness

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Any cognitive impairment that precludes informed consent

          -  Known intolerance or lack of response to Seroquel

          -  Previous enrollment or randomization of treatment in the present study

          -  Participation in another drug trial within 4 weeks prior enrollment into this study

          -  Patients with Diabetes Mellitus

          -  History of allergic reaction or hypersensitivity to Seroquel

          -  Contraindications to magnetic resonance imaging

          -  Treatment with an effective medication for PTSD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Elman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Street Health Center</name>
      <address>
        <city>Somerville</city>
        <state>Massachusetts</state>
        <zip>02143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <results_first_submitted>March 3, 2017</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge Health Alliance</investigator_affiliation>
    <investigator_full_name>Igor Elman</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Post-traumatic Stress Disorder</keyword>
  <keyword>PTSD</keyword>
  <keyword>Seroquel</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Seroquel</title>
          <description>This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Seroquel: This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Seroquel</title>
          <description>This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Seroquel: This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint.</title>
        <description>We will compare patients' symptomatology at baseline vs. at 8 week timepoint
Specify Full Scale Name and Construct (i.e., indicate what the scale measures if not clear from name): Clinician-Administered PTSD Scale (CAPS)
Include all scale ranges (i.e., minimum and maximum scores) required to interpret any values in the data table: 0-136
For each scale range provided, specify which values are considered to be a better or worse outcome: 0-best, 136 worst
If subscales are combined to compute a total score, consider indicating how subscales are combined (summed, averaged, etc.): summed</description>
        <time_frame>8 weeks</time_frame>
        <population>It was predicted that patients will show a change in PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS).</population>
        <group_list>
          <group group_id="O1">
            <title>Seroquel</title>
            <description>This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Seroquel: This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint.</title>
          <description>We will compare patients' symptomatology at baseline vs. at 8 week timepoint
Specify Full Scale Name and Construct (i.e., indicate what the scale measures if not clear from name): Clinician-Administered PTSD Scale (CAPS)
Include all scale ranges (i.e., minimum and maximum scores) required to interpret any values in the data table: 0-136
For each scale range provided, specify which values are considered to be a better or worse outcome: 0-best, 136 worst
If subscales are combined to compute a total score, consider indicating how subscales are combined (summed, averaged, etc.): summed</description>
          <population>It was predicted that patients will show a change in PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Seroquel</title>
          <description>This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Seroquel: This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Igor Elman</name_or_title>
      <organization>Cambridge Health Alliance</organization>
      <phone>(617) 665-1000</phone>
      <email>ielman@challiance.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

